Goldman Sachs’s CareDx CDNA Stock Holding History

Goldman Sachs’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,000	Closed	-$5.49M	–	6248
2021 Q2	$5.49M	Buy	+60,000	New	+$4.77M	﹤0.01%	3259

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's CDNA Position: Q2 2026 in Review

Goldman Sachs reduced its CareDx (CDNA) stake by 4.5% in Q2 2026, selling an estimated $726K and leaving 699,993 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

Goldman Sachs first reported a position in CDNA in Q3 2014 and has held it in 47 quarters since. The position peaked at $57.7M in Q2 2021. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

Goldman Sachs held 699,993 shares of CareDx worth $19.9M as of Q2 2026.
Goldman Sachs sold 33,339 CareDx shares in Q2 2026, an estimated $726K.
CareDx made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2628 holding.
Goldman Sachs first reported a position in CareDx in Q3 2014 and has held it in 47 quarters since.
Goldman Sachs's CareDx position peaked at $57.7M in Q2 2021.
227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.